Skip to main content
Fig. 1 | Journal of Hematology & Oncology

Fig. 1

From: Simultaneously inactivating Src and AKT by saracatinib/capivasertib co-delivery nanoparticles to improve the efficacy of anti-Src therapy in head and neck squamous cell carcinoma

Fig. 1

HNSCC cells exhibit differential response to saracatinib. a The effect of saracatinib on cell viability in different types of cancer cells determined by MTS assays on day 3 after treatment. b The IC50 of saracatinib in 5 different HNSCC cells determined by MTS assays on day 3 after treatment. c Comparison of saracatinib effect on cell viability in various HNSCC cell lines determined by MTS assays on day 3 after treatment. d The phosphorylation levels of Src in HNSCC cells determined by Western blotting. The representative result and quantitative data from three independent experiments were shown in the left and right panels, respectively. **p < 0.01

Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us